Concord Biotech Ltd Falls to 52-Week Low of Rs.1090.85

Stock Price Movement and Market Context

On 23 Feb 2026, Concord Biotech’s share price touched an intraday high of Rs.1125.5, representing a 2.39% increase from the previous close. However, the stock ultimately closed lower, registering a day change of -0.35%. This decline contributed to the stock’s fall to Rs.1090.85, its lowest level in the past 52 weeks. The stock has been on a losing streak for three consecutive days, cumulatively falling by 4.86% during this period.

In comparison, the Sensex index demonstrated resilience, climbing 323.24 points to close at 83,230.07, a 0.5% gain on the day. The Sensex remains 3.52% below its 52-week high of 86,159.02, supported by strong performances from mega-cap stocks. Concord Biotech’s underperformance is further highlighted by its lagging behind the Pharmaceuticals & Biotechnology sector by 0.78% on the same day.

Technically, Concord Biotech is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained bearish momentum in the stock’s price action.

Financial Performance and Valuation Metrics

Concord Biotech’s financial indicators reveal a mixed picture. The company’s operating profit has declined at an annualised rate of -0.34% over the last five years, indicating subdued long-term growth. Recent quarterly results have been negative for three consecutive quarters, with profit before tax (PBT) falling by 15.9% to Rs.79.46 crores compared to the previous four-quarter average. Similarly, profit after tax (PAT) declined by 17.4% to Rs.66.90 crores in the latest quarter.

Return on capital employed (ROCE) for the half-year period stands at 23.48%, which is the lowest recorded in recent times. Return on equity (ROE) remains relatively high at 17.7%, reflecting efficient utilisation of shareholder funds. However, the stock’s valuation appears expensive with a price-to-book value ratio of 6.3, despite trading at a discount relative to its peers’ historical averages.

Over the past year, Concord Biotech’s stock has delivered a negative return of -33.12%, significantly underperforming the Sensex’s positive 10.52% return. Profitability has also contracted by 3.5% during this period, underscoring the challenges faced by the company in maintaining growth momentum.

Long-Term and Recent Performance Trends

Concord Biotech’s performance over the medium to long term has been below par. The stock has underperformed the BSE500 index over the last three years, one year, and three months. This persistent underperformance is reflected in the stock’s declining returns and shrinking profit margins.

The company’s market capitalisation grade is rated at 3, indicating a mid-tier market cap status within its sector. The Mojo Score stands at 34.0 with a Mojo Grade of Sell, which was upgraded from a previous Strong Sell rating on 17 Feb 2026. This suggests a slight improvement in sentiment but still reflects caution regarding the stock’s outlook.

Balance Sheet and Shareholding Structure

Concord Biotech maintains a conservative capital structure with an average debt-to-equity ratio of zero, indicating no reliance on debt financing. This low leverage reduces financial risk and provides flexibility in capital allocation.

The majority shareholding is held by promoters, which often implies stable ownership and potential alignment with shareholder interests. Additionally, the company exhibits high management efficiency, as evidenced by a robust ROE of 19.17%.

Summary of Key Metrics

To summarise, Concord Biotech’s stock has reached a new 52-week low of Rs.1090.85 following a series of declines over recent days. The stock’s performance contrasts with the broader market’s upward trend, highlighting sector-specific and company-specific pressures. Financial results indicate contraction in profits and subdued growth rates, while valuation metrics suggest the stock remains relatively expensive despite recent price falls.

The company’s strong management efficiency and debt-free balance sheet provide some stability, but the overall trend remains cautious given the recent earnings declines and price underperformance.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →